Medigene’s iM-TCR Technology Receives Japanaese Patent

Medigene Expands Patent Portfolio in Japan for iM-TCR Technology Enhancing TCR-T Safety and Efficacy

Overview

Medigene AG has recently received a patent from the Japan Patent Office for its inducible Medigene T cell receptor (iM-TCR), a mechanism designed to regulate the efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies.

Medigene CEO on Efficacy and Safety 

• Selwyn Ho, CEO at Medigene, expressed satisfaction with the patent grant, noting its importance in expanding the company's intellectual property portfolio. 
• He emphasized the potential of the iM-TCR to provide tailored efficacy and safety for individual patients by controlling TCR activity post-administration. 
• Ho also highlighted the iM-TCR as an example of Medigene's End-to-End Platform, which includes various proprietary armoring and enhancement technologies. 
• By combining the iM-TCR with their optimal 3S (sensitive, specific, and safe) TCRs, Medigene aims to deliver innovative solutions that optimize the safety and efficacy of TCR-T therapies.

TCR-T Against Cancer

• TCR-T therapies have demonstrated effectiveness in killing tumor cells, but excessive T cell activation can lead to issues such as premature exhaustion, cell death, and unwanted inflammatory responses. 
• The iM-TCR technology addresses these concerns by modulating TCR surface expression, enabling precise adjustment of activity against tumor cells while reducing inflammatory responses in the body. 
• This feature is particularly promising for sensitive organs affected by sustained inflammatory reactions caused by T cells, such as those seen in brain or liver cancer.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!